
Core Insights - The cancer drug market, particularly antibody-drug conjugates (ADCs), is experiencing significant growth and interest from various companies, as highlighted during the JPMorgan Healthcare Conference in San Francisco [1][2] - Johnson & Johnson's recent $2 billion acquisition of Ambrx Biopharma is indicative of the strategic moves companies are making to enhance their ADC pipelines, with other major players like Pfizer and Merck also engaging in ADC-related deals [2] - Analysts predict continued advancements and deal-making in the ADC space, driven by increased confidence in the technology and the potential for substantial profits, with ADCs projected to represent $31 billion of the $375 billion global cancer market by 2028 [3] Industry Trends - The enthusiasm for ADCs is fueled by their ability to specifically target cancer cells while minimizing damage to healthy cells, contrasting with traditional chemotherapy [1] - The ADC market was valued at approximately $9.7 billion in 2023, indicating a robust foundation for future growth [3] - The fear of missing out (FOMO) among companies not yet involved in the ADC market is likely to drive further entries and investments into this sector [2][3]